Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

The viral illness kills more people in the city than HIV, but antiviral medications may be helping cut its transmission.

are living with chronic infection of hepatitis B or C,” he said. The lawmaker said that a greater percentage of the population remained at risk of infection or death from the viral disease.

Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory effectiveness of ...

The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...

Overall, the association between HBV viral load and HCC risk was linear ... people with chronic hepatitis B are at risk prior to the development of cirrhosis,” she said.

If no other government comes forward to close the funding gap, we will face an alarming increase in transmission,' says Finn Jarle Rode, executive director of The Hepatitis Fund - Anadolu Ajansı ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

We are facing a new threat to global health. The COVID-19 pandemic made it clear to health-care providers, public health practitioners, policy makers, and communities that pathogens do not respect ...

Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing ... to developing potentially life-changing therapeutics for serious viral and liver ...